{
  "abstract": "The therapeutic landscape of advanced hepatocellular carcinoma (HCC) has undergone a paradigm shift with the advent of immune checkpoint blockade (ICB). Since the landmark success of atezolizumab plus bevacizumab in the IMbrave150 trial, immunotherapy has become the standard of care for advanced HCC. Despite these advances, a central unresolved question continues to shape the field: does HCC aetiology influence responsiveness or prognosis following immunotherapy?",
  "authors": [
    {
      "affiliations": [
        "Department of Pathology, The University of Hong Kong, Hong Kong, China",
        "State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China"
      ],
      "name": "Irene Oi-Lin Ng"
    },
    {
      "affiliations": [
        "Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China",
        "China-Singapore Belt and Road Joint Laboratory on Liver Disease Research, The First Hospital of Jilin University, Changchun, Jilin, China"
      ],
      "name": "Guoyue Lyu"
    }
  ],
  "title": "Immunotherapy in HCC: aetiology matters",
  "uid": "102f1d94-fd90-52b3-9ad7-7ccc978e2235"
}